Alentis Therapeutics AG
- Country
- π¨πSwitzerland
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alentis.ch
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
- Conditions
- Squamous Non-small-cell Lung CancerHead and Neck Squamous Cell CarcinomaCervical Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 170
- Registration Number
- NCT06747585
- Locations
- πΊπΈ
Providence Medical Foundation, Fullerton, California, United States
πΊπΈUSC Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈYale Comprehensive Cancer Center, New Haven, Connecticut, United States
Study of ALE.C04 in Patients With Head and Neck Cancer
- Conditions
- Head and Neck CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 21
- Registration Number
- NCT06054477
- Locations
- πΊπΈ
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
πΊπΈUniversity of Southern California USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈYale University Yale Cancer Center, New Haven, Connecticut, United States
Rescue of Nephrons With ALE.F02 (RENAL-F02)
- Conditions
- Glomerulonephritis Rapidly Progressive
- Interventions
- Drug: PlaceboDrug: Immunosuppressive Agents
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 80
- Registration Number
- NCT06047171
- Locations
- π¨πΏ
Vseobecna fakultni nemocnice v Praze, Prague, Czechia
π¨πΏInstitut klinicke a experimentalni mediciny, Praha 4, Czechia
π©π°Aalborg University Hospital, Aalborg, Denmark
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients with Advanced Liver Fibrosis and/or with Mild Cirrhosis
- Conditions
- Advanced liver fibrosis and/or mild liver cirrhosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 37
- Registration Number
- 2024-516455-40-00
- Locations
- π·π΄
Arensia Exploratory Medicine S.R.L., Bucharest, Romania
π·π΄Spitalul Clinic Judetean De Urgenta Cluj, Cluj-Napoca, Romania
πΈπ°Summit Clinical Research s.r.o., Malacky, Slovakia